Related Experiment Video
Updated: Jan 5, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.8K
Correction to: Polatuzumab Vedotin: First Global Approval.
1Springer Nature, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
Drugs
|October 17, 2019
Summary
Polatuzumab Vedotin has received its first global approval for treating certain cancers. This marks a significant advancement in targeted cancer therapy, offering new hope for patients.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- The article details the initial global approval of Polatuzumab Vedotin.
- Roche/GCC funded the transition to open access for wider dissemination.
Purpose of the Study:
- To announce and provide information on the first global approval of Polatuzumab Vedotin.
- To facilitate broader access to the research findings through open access.
Main Methods:
- The article was initially published online without open access.
- A post-publication request led to its open access publication.
Main Results:
- Polatuzumab Vedotin has achieved its first global regulatory approval.
- The publication is now available under a Creative Commons Attribution-NonCommercial license.
Conclusions:
- The approval signifies a milestone in the therapeutic options for specific cancer types.
- Open access ensures wider reach and accessibility of this important oncological development.
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:26FDA Approved Drugs: Changes to Approved Drugs
197
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
197
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
405
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
405
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
424
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
424